Acusphere to Participate in Friedman Billings Ramsey Investor Conference.Business Editors/Health/Medical Writers Friedman Billings Ramsey FBR Group Friedman, Billings, Ramsey Group Inc., or simply FBR, (NYSE:FBR), is a full service investment bank headquartered in Arlington, Virginia that sponsors the FBR Open PGA golf tournament held in Phoenix, Arizona. Investor Conference WATERTOWN, Mass.--(BUSINESS WIRE)--June 1, 2004 Acusphere, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ACUS acus (a´kus) a needle or needle-like process. acus a needle or needle-like process. ) announced today that it is scheduled to present at the Friedman Billings Ramsey 8th Annual Growth Investor Conference at 3:30 PM Eastern Time on Wednesday, June 2, 2004 in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . The presentation will take place at the Millennium Broadway Hotel. The audio portion of the presentation may be heard via webcast, please visit the investor relations Investor relations The process by which the corporation communicates with its investors. section of the Company's website (www.acusphere.com) at least 5 minutes before the presentation. About Acusphere, Inc. Acusphere is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microparticle technology. Acusphere's three initial product candidates are in clinical development and are designed to address large unmet clinical needs within cardiology cardiology Medical specialty dealing with heart diseases and disorders. It began with the 1749 publication by Jean Baptiste de Sénac of contemporary knowledge of the heart. Diagnostic methods improved in the 19th century, and in 1905 the electrocardiograph was invented. , oncology and asthma. These product candidates were created using proprietary technology that enables Acusphere to control the porosity and size of nanoparticles and microparticles in a versatile manner that allows particles to be customized to address the delivery needs of a variety of drugs. Acusphere's lead product candidate, AI-700, is a cardiovascular drug in Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA clinical development. AI-700 is designed to be a preferred alternative to the estimated 9.5 million procedures done each year in the U.S. to detect coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. , the leading cause of death in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . For more information about Acusphere visit the Company's web site at www.acusphere.com. "Acusphere" is trademarks of Acusphere, Inc. The presentation to be made at the above announced conference may contain forward-looking statements, including statements regarding the successful and timely completion of clinical trials, future financing needs, commercial prospects for the Company's product candidates and technology and prospects for new partnering and business relationships. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including anticipated operating losses, uncertainties associated with research, development, testing and related regulatory approvals, unproven markets, future capital needs and uncertainty of additional financing, competition, uncertainties associated with intellectual property, complex manufacturing, high quality requirements for clinical trial materials and the technical challenges associated with obtaining such material, dependence on third-party manufacturers, suppliers and collaborators, loss of key personnel, lack of sales and marketing experience, uncertainties associated with market acceptance and adequacy of reimbursement, technological change, government regulation, and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q Form 10-Q See 10-Q. . Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of such presentation. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of such presentation or to reflect the occurrence of unanticipated events. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion